Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Apr 17;2015(4):CD006754.
doi: 10.1002/14651858.CD006754.pub4.

Anticonvulsants for cocaine dependence

Silvia Minozzi  1 , Michela Cinquini, Laura Amato, Marina Davoli, Michael F Farrell, Pier Paolo Pani, Simona Vecchi
Affiliations
Meta-Analysis

Anticonvulsants for cocaine dependence

Silvia Minozzi et al. Cochrane Database Syst Rev. .

Abstract

Background: Cocaine dependence is a major public health problem that is characterised by recidivism and a host of medical and psychosocial complications. Although effective pharmacotherapy is available for alcohol and heroin dependence, none is currently available for cocaine dependence, despite two decades of clinical trials primarily involving antidepressant, anticonvulsivant and dopaminergic medications. Extensive consideration has been given to optimal pharmacological approaches to the treatment of individuals with cocaine dependence, and both dopamine antagonists and agonists have been considered. Anticonvulsants have been candidates for use in the treatment of addiction based on the hypothesis that seizure kindling-like mechanisms contribute to addiction.

Objectives: To evaluate the efficacy and safety of anticonvulsants for individuals with cocaine dependence.

Search methods: We searched the Cochrane Drugs and Alcohol Group Trials Register (June 2014), the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 6), MEDLINE (1966 to June 2014), EMBASE (1988 to June 2014), the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1982 to June 2014), Web of Science (1991 to June 2014) and the reference lists of eligible articles.

Selection criteria: All randomised controlled trials and controlled clinical trials that focus on the use of anticonvulsant medications to treat individuals with cocaine dependence.

Data collection and analysis: We used the standard methodological procedures expected by The Cochrane Collaboration.

Main results: We included a total of 20 studies with 2068 participants. We studied the anticonvulsant drugs carbamazepine, gabapentin, lamotrigine, phenytoin, tiagabine, topiramate and vigabatrin. All studies compared anticonvulsants versus placebo. Only one study had one arm by which the anticonvulsant was compared with the antidepressant desipramine. Upon comparison of anticonvulsant versus placebo, we found no significant differences for any of the efficacy and safety measures. Dropouts: risk ratio (RR) 0.95, 95% confidence interval (CI) 0.86 to 1.05, 17 studies, 20 arms, 1695 participants, moderate quality of evidence. Use of cocaine: RR 0.92, 95% CI 0.84 to 1.02, nine studies, 11 arms, 867 participants, moderate quality of evidence; side effects: RR 1.39, 95% CI 1.01 to 1.90, eight studies, 775 participants; craving: standardised mean difference (SMD) -0.25, 95% CI -0.59 to 0.09, seven studies, eight arms, 428 participants, low quality of evidence.

Authors' conclusions: Although caution is needed when results from a limited number of small clinical trials are assessed, no current evidence supports the clinical use of anticonvulsant medications in the treatment of patients with cocaine dependence. Although the findings of new trials will improve the quality of study results, especially in relation to specific medications, anticonvulsants as a category cannot be considered first-, second- or third-line treatment for cocaine dependence.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

1
1
2
2
Study flow diagram of the updated version.
3
3
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
4
4
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Any anticonvulsant versus placebo, Outcome 1 Dropout.
1.2
1.2. Analysis
Comparison 1 Any anticonvulsant versus placebo, Outcome 2 Use of cocaine (self reported or objective).
1.3
1.3. Analysis
Comparison 1 Any anticonvulsant versus placebo, Outcome 3 Side effect.
1.4
1.4. Analysis
Comparison 1 Any anticonvulsant versus placebo, Outcome 4 Craving.
1.5
1.5. Analysis
Comparison 1 Any anticonvulsant versus placebo, Outcome 5 Severity of dependence (ASI).
1.6
1.6. Analysis
Comparison 1 Any anticonvulsant versus placebo, Outcome 6 Severity of dependence (CGI‐O).
1.7
1.7. Analysis
Comparison 1 Any anticonvulsant versus placebo, Outcome 7 Depression (HAM‐D).
1.8
1.8. Analysis
Comparison 1 Any anticonvulsant versus placebo, Outcome 8 Anxiety (HAM‐A).
1.9
1.9. Analysis
Comparison 1 Any anticonvulsant versus placebo, Outcome 9 Compliance.
1.10
1.10. Analysis
Comparison 1 Any anticonvulsant versus placebo, Outcome 10 Compliance.
2.1
2.1. Analysis
Comparison 2 Single anticonvulsant versus placebo, Outcome 1 Dropout.
2.2
2.2. Analysis
Comparison 2 Single anticonvulsant versus placebo, Outcome 2 Use of cocaine (self reported or objective).
2.3
2.3. Analysis
Comparison 2 Single anticonvulsant versus placebo, Outcome 3 Side effects.
3.1
3.1. Analysis
Comparison 3 Anticonvulsant (carbamazepine) vs antidepressant (desipramine), Outcome 1 Dropout.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Berger 2005 arm a {published data only}
    1. Berger PS, Winhusen TM, Somoza EC, Harrer JM, Mezinskis JP, Leiderman DB, et al. A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction 2005;100(Suppl 1):58‐67. - PubMed
Berger 2005 arm b {published data only}
    1. Berger PS, Winhusen TM, Somoza EC, Harrer JM, Mezinskis JP, Leiderman DB, et al. A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction 2005;100(Suppl 1):58‐67. - PubMed
Bisaga 2006 {published data only}
    1. Bisaga A, Aharonovich E, Garawi F, Levin FR, Rubin E, Raby WN, et al. A randomised placebo‐controlled trial of gabapentin for cocaine dependence. Drug and Alcohol Dependence 2006;81(3):267‐74. - PubMed
Brodie 2009 {published data only}
    1. Brodie JD, Case BG, Figueroa E, Dewey SL, Robinson JA, Wanderling JA, et al. Randomized, double‐blind, placebo‐controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. American Journal of Psychiatry 2009;166(11):1269‐77. - PubMed
Brown 2012 {published data only}
    1. Brown ES. Comparative medication strategies in treatment trials for bipolar disorder and substance use disorders. Bipolar Disorder 2013;15:33.
    1. Brown ES, Sunderajan P, Hu LT, Sowell SM, Carmody TJ. A randomized, double‐blind, placebo‐controlled, trial of lamotrigine therapy in bipolar disorder, depressed or mixed phase and cocaine dependence. Neuropsychopharmacology 2012;37(11):2347‐54. - PMC - PubMed
Campbell 1994 arm a {published data only}
    1. Campbell JL, Thomas HM, Gabrielli W, Liskow BI, Powell BJ. Impact of Desipramine or Carbamazepine on patient retention in outpatient cocaine treatment: preliminary findings. Journal of Addictive Diseases 1994;13(4):191‐9. - PubMed
Campbell 1994 arm b {published data only}
    1. Campbell JL, Thomas HM, Gabrielli W, Liskow BI, Powell BJ. Impact of Desipramine or Carbamazepine on patient retention in outpatient cocaine treatment: preliminary findings. Journal of Addictive Diseases 1994;13(49:191‐9. - PubMed
Campbell 2003 arm a {published data only}
    1. Campbell J, Nickel EJ, Penick EC, Wallace D, Gabrrelli WF, Rowe C, et al. Comparison of desipramine or carbamazepine to placebo for crack cocaine dependent patients. American Journal of Addiction 2003;12:122‐36. - PubMed
    1. Campbell J, Nickel EJ, Penlick EC, Liskow B, Powell BJ. Gender differences in pharmacologic treatment for cocaine dependence. NIDA Research Monograph 1999:54.
    1. Campbell L, Thomas HM, Gabrielli WF, Samuelson SD. Efficacy and compliance with carbamazepine and desipramine versus placebo for cocaine abusers. NIDA Research Monograph 1996;162:147.
Campbell 2003 arm b {published data only}
    1. Campbell J, Nickel EJ, Penick EC, Wallace D, Gabrrelli WF, Rowe C, et al. Comparison of desipramine or carbamazepine to placebo for crack cocaine dependent patients. American Journal of Addiction 2003;12:122‐36. - PubMed
Cornish 1995 {published data only}
    1. Cornish JW, Manny I, Fudala PJ, Neal S, Poole SA, Volpicelli P, et al. Carbamazepine treatment for cocaine dependence. Drug and Alcohol Dependence 1995;38(3):221‐7. - PubMed
Crosby 1996 {published data only}
    1. Crosby RD, Pearson VL, Eller C, Winegarden T, Graves NL. Phenytoin in the treatment of cocaine abuse: a double blind study. Clinical Pharmacology & Therapeutics 1996;59(4):458‐68. - PubMed
Gonzalez 2007 arm a {published data only}
    1. Gonzalez G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsai K, et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone‐treated patients. Drug and Alcohol Dependence 2007;87(1):1‐9. - PubMed
    1. Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, et al. Tiagabine increases cocaine‐free urine in cocaine‐dependent methadone‐treated patients: results of a randomised pilot study. Addiction 2003;98(11):1625‐32. - PubMed
Gonzalez 2007 arm b {published data only}
    1. Gonzalez G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsai K, et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone‐treated patients. Drug and Alcohol Dependence 2007;87(1):1‐9. - PubMed
Halikas 1997 arm a {published data only}
    1. Halikas JA, Crosby RD, Koop LP, Crea F, Nugent SM, Carlson GA. Daily monitored cardiovascular effects of Carbamazepine in chronic crack cocaine use. Psychopharmacological Bullettin 1991;27(3):345‐51. - PubMed
    1. Halikas JA, Crosby RD, Pearson VL, Graves NM. A randomised double‐blind study of carbamazepine in the treatment of cocaine abuse. Clinical Pharmacology and Therapeutics 1997;62(1):89‐105. - PubMed
Halikas 1997 arm b {published data only}
    1. Halikas JA, Crosby RD, Koop LP, Crea F, Nugent SM, Carlson GA. Daily monitored cardiovascular effects of Carbamazepine in chronic crack cocaine use. Psychopharmacological Bullettin 1991;27(3):345‐51. - PubMed
    1. Halikas JA, Crosby RD, Pearson VL, Graves NM. A randomised double‐blind study of carbamazepine in the treatment of cocaine abuse. Clinical Pharmacology and Therapeutics 1997;62(1):89‐105. - PubMed
Johnson 2013 {published data only}
    1. Johnson BA, Ait‐Daoud N, Wang XQ, Penberthy K, Javors MA, Seneviratne C, Liu L. Topiramate for the treatment of cocaine addiction: a randomised clinical trial. JAMA Psychiatry 2013;70(12):1388‐46. - PubMed
Kampman 2004 {published data only}
    1. Kampan KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug and Alcohol Dependence 2004;75(3):233‐40. - PubMed
Kampman 2013 {published data only}
    1. Kampman K, Pettinati H, Lynch K, Jones A, Varillo K, O'Brian C. A double‐blind, placebo controlled trial of topiramate for the treatment of comorbid alcohol and cocaine dependence. Neuropsychopharmacology. 2010; Vol. 35(Suppl 1):S207.
    1. Kampman KM, Pettinati HM, Lynch KG, et al. Topiramate for the treatment of comorbid alcohol and cocaine dependence. Proceedings of the 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence;. Hollywood, Florida, 2011; Vol. 84:Abstract no: 334.
    1. Kampman KM, Pettinatia HM, Lyncha KG, Spratt BK, Wierzbickic MR, O'Briena CP. A double‐blind, placebo‐controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug and Alcohol Dependence 2013;133:94‐9. - PMC - PubMed
Kranzler 1995 {published data only}
    1. Hersh D, Bauer LO, Kranzler HR. Carbamazepine and cocaine‐cue reactivity. Drug and Alcohol Dependence 1995;39:213‐21. - PubMed
    1. Kranzler HR, Bauer LO, Hersh D, Klinghoffer V. Carbamazepine treatment of cocaine dependence: a placebo‐controlled trial. Drug and Alcohol Dependence 1995;38(3):203‐11. - PubMed
Montoya 1994 {published data only}
    1. Montoya ID, Levin FR, Fudala PJ, Gorelick DA. Double‐blind comparison of carbamazepine and placebo for treatment of cocaine dependence. Drug and Alcohol Dependence 1995;38(3):213‐9. - PMC - PubMed
Nuijten 2014 {published data only}
    1. Nuijten M, Blanken P, Brink W, Hendriks V. Cocaine Addiction Treatments to improve Control and reduce Harm (CATCH): new pharmacological treatment options for crack‐cocaine dependence in the Netherlands. BMC Psychiatry 2011;11:135. - PMC - PubMed
    1. Nuijten M, Blanken P, Brink W, Hendriks V. Treatment of crack‐cocaine dependence with topiramate: a randomized controlled feasibility trial in The Netherlands. Drug and Alcohol Dependence 2014;138:177‐84. - PubMed
Somoza 2013 {published data only}
    1. Somoza EC, Winship D, Gorodetzky CW, Lewis D, Ciraulo DA, Galloway GP, et al. A multisite, double‐blind, placebo‐controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence. JAMA Psychiatry 2013;70(6):630‐7. - PubMed
Umbricht 2014 {published data only}
    1. Umbricht A, DeFulio A, Tompkins DA. Topiramate and contingency management in the treatment of cocaine dependence: a randomized controlled trial. Proceedings of the 74th Annual Scientific Meeting of the College on Problems of Drug Dependence;. Palm Springs, CA, 2012; Vol. Abstract no: 681.
    1. Umbricht A, DeFulio A, Winstanley EL, Tompkins DA, Peirce J, Mintzer MZ, et al. Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. Drug and Alcohol Dependence 2014;140:92‐100. - PMC - PubMed
Winhusen 2005 {published data only}
    1. Winhusen TM, Somoza EC, Harrer JM, Mezinskis JP, Montgomery MA, Goldsmith RJ, et al. A placebo‐controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 2005;100(Suppl 1):68‐77. - PubMed
Winhusen 2007 {published data only}
    1. Winhusen T, Somoza E, Ciraulo DA, Harrer JM, Goldsmith RJ, Grabowski J, et al. A double‐blind, placebo‐controlled trial of tiagabine for the treatment of cocaine dependence. Drug and Alcohol Dependence 2007;91(2‐3):141‐8. - PubMed

References to studies excluded from this review

Ahmadi 2006 {published data only}
    1. Ahmadi J, Kampman K, Dackis C. Outcome predictors in cocaine dependence treatment trials. The American Journal of Addiction Psychiatry 2006;15(6):434‐9. - PubMed
Brady 2002 {published data only}
    1. Brady KT, Sonne SC, Malcolm RJ, Randall CL. Carbamazepine in the teratment of cocaine dependence: subtyping by affective disorders. Experimental and Clinical Pharmacology 2002;10(3):276‐85. - PubMed
Brown 2003 {published data only}
    1. Brown ES, Nejtek VA, Perantie DC, Orsulak PJ, Bobadilla LB. Lamotrigine in patients with bipolar disorder and cocaine dependence. Journal of Clinical Psychiatry 2003;64(2):198‐201. - PubMed
Campbell 2001 {unpublished data only}
    1. Campbell J, Gorodetzky C, Nickel J, Pennick E. Does worse predict better? Characteristics and outcomes of volunteers for a medication trial or Psychosocial trial. Drud and Alcohol Dependence. Sixty‐Thrid Annual Scientific Meetind Scottsdale, Arizona. 2001; Vol. Vol. 63 supplement 1, S23.
Cornish 1995 b {unpublished data only}
    1. Cornish JW, Maany I, Fudala PJ, Poole SA, O'Brien CP. An analysis of factors influencing subject participation in a trial of carbamazepine for cocaine dependence treatment. NIDA Research Monograph 1995;135:312.
Elkashef 2005 {published data only}
    1. Elkashef A, Holmes TH, Bloch DA, Shoptaw S, Kampman K, Reid MS. Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence. Addiction 2005;100(Suppl 1):91‐101. - PubMed
Gonzalez 2003 {published data only}
    1. Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, et al. Tiagabine increases cocaine‐free urine in cocaine‐dependent methadone‐treated patients: results of a randomised pilot study. Addiction 2003;98(11):1625‐32. - PubMed
Gorelick 1994 {published data only (unpublished sought but not used)}
    1. Gorelick DA, Weinhold LL, Cone EJ, Henningfield JE. Carbamazepine (CBS) does not alter cocaine self‐administration in human cocaine addicts. NIDA Research Monograph 1994;141:137.
Halikas 1989 {published data only}
    1. Halikas J, Kemp K, Kuhn K, Carlson G, Crea F. Carbamazepine for cocaine addiction. The Lancet 1989;1(8638):623‐4. - PubMed
Halikas 1991 {published data only}
    1. Halikas JA, Crosby RD, Carlson GA, Crea F, Graves NM, et al. Cocaine reduction in unmotivated crack users using carbamazepine versus placebo in a short term, double blind cross over design. Clinical Pharmacology & Therapeutics 1991;50:81‐95. - PubMed
Haney 2005 {published data only}
    1. Haney M, Hart C, Collins ED, Foltin RW. Smoked cocaine discrimination in humans: effects of gabapentin. Drug and Alcohol Dependence 2005;80(1):53‐61. - PubMed
Hart 2004 {published data only}
    1. Hart CL, Waerd AS, Collins ED, Haney M, Foltin RW. Gabapentin maintenance decreases smoked cocaine‐related subjective effects, but not self‐administration by humans. Drug and Alcohol Dependence 2004;73(3):279‐87. - PubMed
Hart 2007 {published data only}
    1. Hart CL, Haney M, Collins ED, Rubin E, Foltin RW. Smoked cocaine self‐administration by humans is not reduced by large gabapentin maintenance doses. Drug and Alcohol Dependence 2007;86(2‐3):274‐7. - PubMed
Hatsukami 1991 {published data only}
    1. Hatsukami D, Keenan R, Halikas J, Pentel PR, Brauer LH. Effects of carbamazepine on acute responses to smoked cocaine‐base in human cocaine users. Psychopharmacology 1991;104:120‐4. - PubMed
Johnoson 2005 {published data only}
    1. Johnson BA. Recent advances in the development of treatments for alcohol and cocaine dependence. CNS Drugs 2005;19(10):873‐96. - PubMed
Kampman 2005 {published data only}
    1. Kampman KM, Leiderman D, Holmes T, LoCastro J, Bloch DA, Reid MS, et al. Cocaine rapid efficacy screening trials (CREST): lessons learned. Addiction 2005;100(Suppl 1):102‐10. - PubMed
Kemp 2009 {published data only}
    1. Calabrese JR, Kemp DE, Ganocy SJ, et al. A 6‐month, pilot, double‐blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for dual diagnosis rapid‐cycling bipolar disorder. International Journal of Psychiatry in Clinical Practice. 2007; Vol. 11(Suppl 1):15‐6.
    1. Kemp DE, Gao K, Ganocy SJ, et al. A 6‐month, double‐blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid‐cycling bipolar disorder and co‐occurring substance abuse or dependence. Journal of Clinical Psychiatry 2 2009;70(1):113‐21. - PMC - PubMed
Khun 1989 {published data only}
    1. Kuhn KL, Halikas JA, Kemp KD. Carbamazepine treatment of cocaine dependence in methadone maintenance patient with dual opiate‐cocaine addiction. NIDA Research Monograph 1989;95:316‐7. - PubMed
Leiderman 2005 {published data only}
    1. Leiderman DB, Shoptaw S, Montgomery A, Bloch DA, Elkashef A, LoCastro JL, et al. Cocaine rapid efficacy screening trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence. Addiction 2005;100(Suppl 1):1‐11. - PubMed
Llopis Llacer 2008 {published data only}
    1. Llopis Llacer JJ, Aguilella AC. Efficacy of oxcarbazepine treatment in patients diagnosed with cocaine abuse/dependence. Adicciones 2008;20(3):263‐70. - PubMed
Mancino 2014 {published data only}
    1. Mancino MJ, Feldman Z, Chopra M, Cargile CS, Oliveto A. Randomized placebo controlled trial of sertraline and sertraline plus gabapentin in depressed, recently abstinent cocaine‐dependent patients. Proceedings of the 71th Annual Scientific Meeting of the College on Problems of Drug Dependence. Nevada USA: Reno/Sparks, 2009; Vol. 94.
    1. Mancino MJ, McGaugh J, Chopra MP, et al. Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine‐dependent patients with depressive symptoms. Journal of Clinical Psychopharmacology 2014;34(2):234‐9. - PMC - PubMed
Mariani 2012 {published data only}
    1. Mariani JJ, Pavlicova M, Bisaga A, Nunes EV, Brooks DJ, Levin FR. Extended‐release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biological Psychiatry 2012;72(11):950‐6. - PMC - PubMed
Reid 2005 {published data only}
    1. Reid MS, Casadonte P, Baker S, Sanfilippo M, Braunstein D, Hitzemann R, et al. A placebo‐controlled screening trial of olanzapine, valproate and coenzyme Q10/L‐carnitine for the treatment of cocaine dependence. Addiction 2005;100(Suppl 1):43‐57. - PubMed
Reid 2009 {published data only}
    1. Reid MS, Thakkar V. Valproate treatment and cocaine cue reactivity in cocaine dependent individuals. Drug and Alcohol Dependence 2009;102(1‐3):144‐50. - PMC - PubMed
Reis 2008 {published data only}
    1. Reis AD, Castro LA, Faria R, Laranjeira R. Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. Rev Bras Psiquiatr 2008;30(2):132‐5. - PubMed
Salloum 2007 {published data only}
    1. Salloum IM, Douaihy A, Cornelius JR, Kirisci L, Kelly TM, Hayes J. Divalproex utility in bipolar disorder with co‐occurring cocaine dependence: a pilot study. Addictive Behaviors 2007;32(2):410‐5. - PubMed
Sofuoglu 1999 {published data only}
    1. Sofuoglu M, Pentel PR, Bliss RL, Goldman AI, Hatsukami DK. Effects of phenytoin on cocaine self‐administration in humans. Drug and Alcohol Dependence 1999;53(3):273‐5. - PubMed
Sofuoglu 2005 {published data only}
    1. Sofuoglu M, Poling J, Mitchell E, Kosten TR. Tiagabine affects the subjective response to cocaine in humans. Pharmacology, Biochemistry and Behavior 2005;82(3):569‐73. - PubMed
Vocci 2005 {published data only}
    1. Vocci FJ, Elkashef A. Pharmacotherapy and other treatments for cocaine abuse and dependence. Current Opinion in Psychiatry 2005;18:235‐70. - PubMed
Winter 2000 {published data only}
    1. Winther LC, Saleem R, McCance‐Katz EF, Rosen MI, Hameedi FA, Pearsall HR, et al. Effects of lamotrigine on behavioral and cardiovascular responses to cocaine in human subjects. American Journal on Drug and Alcohol Abuse 2000;26(1):47‐59. - PubMed
Zullino 2004 {published data only}
    1. Zullino DF, Khazaal Y, Hattenschwiler J, Borgeat F, Besson J. Anticonvulsant drugs in the treatment of substance withdrawal. Drugs of Today 2004;40(7):603‐19. - PubMed

References to studies awaiting assessment

Gonzalez 2009 {published data only}
    1. Gonzalez G, Romero‐Gonzalez M, Desai R, et al. Myoclonus cases associated with tiagabine treatment for cocaine and opioid dependent patients. American Journal on Addictions 2009;18(4):324.
Llorens 2007 {published data only}
    1. Llorens N, Perello MJ, Senchez A, et al. Exposuure techniques versus topiramate treatment on cocaine addiction. Proceedings of the 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007.
Sherwood Brown 2011 {published data only}
    1. Sherwood Brown E, Sunderajan P, Hu LT, Sowell S, Carmody T. Lamotrigine in bipolar disorder, depressed or mixed phase and cocaine dependence. Neuropsychopharmacology 2011;36:S425‐6. - PMC - PubMed

References to ongoing studies

Jenkins‐Mendoza 2005 {unpublished data only}
    1. Effectiveness of topiramate in treating cocaine‐dependent individuals. Ongoing study October 2005.
NCT00086255 {unpublished data only}
    1. Tiagabine for the treatment of cocaine dependence. Ongoing study October 2002.
NCT00448825 {unpublished data only}
    1. Novel pharmacotherapy for dual dependence. Ongoing study March 2007.
NCT00577005 {unpublished data only}
    1. Effectiveness of tiagabine for cocaine dependence in methadone maintenance individuals. Ongoing study December 2004.
NCT00593125 {unpublished data only}
    1. Efficacy of levetiracetam in cocaine‐abusing methadone maintained patients (Keppra‐DB). Ongoing study July 2007.
NCT01281202 {unpublished data only}
    1. Vigabatrin for the treatment of cocaine dependency. Ongoing study January 2011.
NCT01335867 {unpublished data only}
    1. A phase II, double‐blind, placebo‐controlled, pilot trial of vigabatrin for the treatment of cocaine and alcohol dependence. Ongoing study April 2011.
NCT01811940 {unpublished data only}
    1. Multi‐centre trial of combined pharmacotherapy to treat cocaine dependence (TACT2). Ongoing study Starting date of trial not provided. Contact author for more information.
NTR2576 {unpublished data only}
    1. New pharmacotherapeutic treatment options for crack cocaine‐dependent people in the Netherlands. ‐ CATCH‐study. Ongoing study April 2010.
RBR‐3vwfjs {unpublished data only}
    1. The use of topiramate in the crack addiction. Ongoing study February 2013.

Additional references

Alvarez 2010
    1. Alvarez Y, Farré M, Fonseca F, Torrens M. Anticonvulsant drugs in cocaine dependence: a systematic review and meta‐analysis. Journal of Substance Abuse Treatment 2010;38(1):66‐73. - PubMed
Amato 2007
    1. Amato L, Minozzi S, Pani PP, Davoli M. Antipsychotic medication for cocaine dependence. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006306.pub2] - DOI - PubMed
Amato 2011
    1. Amato L, Minozzi S, Pani PP, Solimini R, Vecchi S, Zuccaro P, et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD003352.pub3] - DOI - PubMed
Anton 1996
    1. Anton RF, Moak DH, Latham PK. The obsessive compulsive drinking scale:a new method of assessing outcome in alcoholism treatment studies. Archives of General Psychiatry 1996;53:225‐31. - PubMed
Beck 1961
    1. Beck AT, Word CH, Mendelson M, Mock J, Rebaugh J. An inventory for measuring depression. Archives of General Psichiatry 1961;4:461‐71. - PubMed
Campbell 1999
    1. Campbell UC, Lac ST, Carroll ME. Effects of baclofen on maintenance and reinstatement of intravenous cocaine self‐administration in rats. Psychopharmacology 1999;143(2):209‐14. - PubMed
Castells 2010
    1. Castells X, Casas M, Pérez‐Mañá C, Roncero C, Vidal X, Capellà D. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD007380.pub3] - DOI - PubMed
Cohen 2014
    1. Cohen J, Dervaux A, Laqueille X. Topiramate in substance‐related and addictive disorders. Presse Medicale 2014;43(9):892‐901. - PubMed
Crosby 1991
    1. Crosby RD, Halikas JA, Carlson G. Pharmacotherapeutic interventions for cocaine abuse: present practices and future directions. Journal of Addictive Diseases 1991;10(4):13‐30. - PubMed
Czapinski 2005
    1. Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Current Topics in Medicinal Chemistry 2005;5(1):3‐14. - PubMed
Degenhardt 2012
    1. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012;379:55‐70. - PubMed
Di Chiara 1988
    1. Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Sciences of the United States of America 1988;85(14):5274‐8. - PMC - PubMed
Drevets 1999
    1. Drevets WC, Price JC, Kupfer DJ, Kinahan PE, Lopresti B, Holt D, et al. PET measures of amphetamine‐induced dopamine release in ventral versus dorsal striatum. Neuropsychopharmacology 1999;21(6):694‐709. - PubMed
Drevets 2001
    1. Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, et al. Amphetamine‐induced dopamine release in human ventral striatum correlates with euphoria. Biological Psychiatry 2001;49(2):81‐96. - PubMed
DSM‐IV‐R
    1. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Association, 1994.
EMCDDA 2006
    1. EMCDDA. The state of the drugs problem in the European Union and Norway. The State of the Drug Problem in the European Union and Norway. Luxemburg: European Monitoring Centre for Drug and Drug Abuse, 2006.
EMCDDA 2012
    1. EMCDDA. The State of the Drug Problem in Europe. Annual Report. Luxemburg: European Monitoring Centre for Drug and Drug Abuse, 2012.
EMCDDA 2014
    1. EMCDDA. European Drug Report: Trends and Developments. European Drug Report: Trends and Developments. Luxemburg: European Monitoring Centre for Drugs and Drug Addiction, 2014.
Grade 2004
    1. The GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490‐4. - PMC - PubMed
Guy 1976
    1. Guy W. Assessment Manual for Psychopharmacology. Publication ADM 76‐338. Washington DC: US Department of Health Education and Welfare, 1976.
Guyatt 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924‐6. - PMC - PubMed
Guyatt 2011
    1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64:383‐94. - PubMed
Halikas 1991
    1. Halikas JA, Kuhn KL, Crosby R, Carlson G, Crea F. The measurement of craving in cocaine patients using the Minnesota Cocaine Craving Scale. Comprehensive Psychiatry 1991;32:22‐7. - PubMed
Hamilton 1959
    1. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32(1):50‐5. - PubMed
Hamilton 1967
    1. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 1967;6(4):278‐96. - PubMed
Harvey 2004
    1. Harvey JA. Cocaine effects on the developing brain: current status. Neuroscience & Biobehavioral Reviews 2004;27(8):751‐64. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane‐handbook.org, 2011.
Karila 2011
    1. Karila L, Reynaud M, Aubin HJ, Rolland B, Guardia D, Cottencin O, Benyamina A. Pharmacological treatments for cocaine dependence: is there something new?. Current Pharmaceutical Design 2011;17(14):1359‐68. - PubMed
Knapp 2007
    1. Knapp WP, Soares BGO, Farrel M, Lima MS. Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006754.pub3.] - DOI - PubMed
Koob 1997
    1. Koob GF, Nestler EJ. The neurobiology of drug addiction. Journal of Neuropsychiatry and Clinical Neurosciences 1997;9(3):482‐97. - PubMed
Kranzler 1995
    1. Kranzler HR, Bauer LO, Hersh D, Klinghoffer V. Carbamazepine treatment of cocaine dependence: a placebo‐controlled trial. Drug and Alcohol Dependence 1995;38(3):203‐11. - PubMed
Kushner 1999
    1. Kushner SA, Dewey SL, Kornetsky C. The irreversible gamma‐aminobutyric acid (GABA) transaminase inhibitor gamma‐vinyl‐GABA blocks cocaine self‐administration in rats. Journal of Pharmacology and Experimental Therapeutics 1999;290(2):792‐802. - PubMed
Landmark 2007
    1. Landmark CJ. Targets for antiepileptic drugs in the synapse. Medical Science Monitor 2007;13(1):RA1‐7. - PubMed
Lima Reisser 2000
    1. Lima Reisser A, Lima MS, Soares BGO, Farrell M. Carbamazepine for cocaine dependence. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD002023.pub2] - DOI - PMC - PubMed
McLellan 1992
    1. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The fifth edition of the Addiction Severity Index. Journal Substance Abuse Treatment 1992;9(3):199‐213. - PubMed
Minozzi 2008
    1. Minozzi S, Amato L, Davoli M, Farrell MF, Lima Reisser AARL, Pani PP, et al. Anticonvulsants for cocaine dependence. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD006754.pub3] - DOI - PubMed
Mulvaney 1999
    1. Mulvaney FD, Alterman AI, Boardman CR, Kampman K. Cocaine abstinence symptomatology and treatment attrition. Journal of Substance Abuse Treatment 1999;16:129‐35. - PubMed
NSDUH 2011
    1. Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality, 2011.
Pani 2010
    1. Pani PP, Trogu E, Vacca R, Amato L, Vecchi S, Davoli M. Disulfiram for the treatment of cocaine dependence. Cochrane Database of Systematic Reviews 2010, Issue 1. [10.1002/14651858.CD007024.pub2] - PubMed
Pani 2011
    1. Pani PP, Trogu E, Vecchi S, Amato L. Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD002950.pub3] - DOI - PubMed
Shinn 2010
    1. Shinn AK, Greenfield SF. Topiramate in the treatment of substance‐related disorders: a critical review of the literature. Journal of Clinical Psychiatry 2010;71(5):634‐48. - PMC - PubMed
Shunemann 2006
    1. Schünemann HJ, Jaeschke R, Cook D, Bria W, El‐Solh A, Ernst A, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. American Journal of Respiratory and Critical Care Medicine 2006;174:605‐14. - PubMed
Somoza 1995
    1. Somoza E, Dyrenforth S, Goldsmith J, Mezinskis J, Cohen M. In search of a universal drug craving scale. Annual Meeting of the American Psychiatric Association. 1995.
Spielberg 1983
    1. Spielberg DC. State‐Trate Anxiety Inventory. Palo Alto CA: Consulting Psychologist Press, 1983.
UNODC 2013
    1. UNODC, World Drug Report 2013 (United Nations publication, Sales No. E.13.XI.6).
Volkow 2003
    1. Volkow ND, Fowler JS, Wang GJ. The addicted human brain: insights for imaging studies. Journal of Clinical Investigation 2003;111(10):1444‐51. - PMC - PubMed

Publication types

MeSH terms

Substances